Immunological Evaluation of IgM And IgG Antibodies and Complement Components C3 and C4 in Thalassemia Patients with Toxoplasma Gondii Infection
Keywords:
Thalassemia, Toxoplasma Gondii, Complement system, Antibodies, IgM, IgGAbstract
Toxoplasmosis is known to be transmissible through blood transfusion, especially from asymptomatic, seropositive individuals during the acute phase. Patients with thalassemia are particularly vulnerable to such opportunistic infections, including Toxoplasma gondii. This study aimed to evaluate the levels of Toxoplasma-specific IgG, IgM, and IgA antibodies, along with complement components C3 and C4, in thalassemia patients with and without toxoplasmosis infection. A significant difference (P < 0.001) was observed in all immunological markers when comparing patient groups to the negative control group. Additionally, both thalassemia groups (with and without toxoplasmosis) showed significant differences compared to the toxoplasmosis-positive control group (P < 0.001). Notably, thalassemia patients with toxoplasmosis exhibited higher levels of Toxoplasma-specific antibodies and altered complement levels compared to thalassemia patients without the infection (P < 0.001). These findings suggest an altered immunological profile in thalassemia patients, particularly when co-infected with T. gondii, highlighting the importance of monitoring such markers in this vulnerable population.
References
[1] Shihab, R.N.; Al-Aubaidi, I.K.; "Toxoplasmosis in thalassemic Iraqi patients: serological and hematological study". Roy. J. Infect. Dis. 27(2): 100-106, 2024.
[2] Ali, S.; Mumtaz, S.; Shakir, H.A.; Khan, M.; Tahir, H.M.; Mumtaz, S.; Khan, M.A.; "Current status of beta-thalassemia and its treatment strategies". Mol. Genet. Genomic Med. 9(12): e1788, 2021.
[3] Thein, S.L.; "Molecular basis of β thalassemia and potential therapeutic targets". Blood Cells Mol. Dis. 70: 54-65, 2018.
[4] Lei, M.; Sun, L.; Luo, X.S.; Yang, X.; Yu, F.; Chen, X.; Wang, Z.; "Distinguishing iron deficiency anemia from thalassemia by the red blood cell lifespan with a simple CO breath test: a pilot study". J. Breath Res. 13(2): 026007, 2019.
[5] Bloch, E.M.; "Transfusion-transmitted infections". Ann. Blood 7(20): 1-19, 2022.
[6] Mousa, N.M.; Nahab, H.M.; "Serological detection and hematological changes associated with toxoplasmosis in thalassemia patients in Al-Samawah province". Int. J. Pharm. Res. 12(4): 872-876, 2020.
[7] Al-Hadraawy, S.K.; Alzeyadi, M.; Shakir, A.; Al-Dujaili, A.; "Detection of Toxoplasma gondii genotypes in abortion women by RFLP-PCR in Al-Najaf Al-Ashraf province". J. Breath Res. 5: 1-7, 2019.
[8] Attias, M.; Teixeira, D.E.; Benchimol, M.; Vommaro, R.C.; Crepaldi, P.H.; De Souza, W.; "The life-cycle of Toxoplasma gondii reviewed using animations". Parasites Vectors 13(1): 588, 2020.
[9] Silva, R.B.; Ramalho, A.S.; Cassorla, R.M.S.; "Anemia falciforme como problema de saúde pública no Brasil". Rev. Saude Publica 27(1): 54-58, 1993.
[10] Higgs, D.R.; Engel, J.D.; Stamatoyannopoulos, G.; "Thalassaemia". Lancet 379(9813): 373-383, 2012.
[11] Greene, D.N.; Vaughn, C.P.; Crews, B.O.A.; Garwal, A.M.; "Advances in detection of hemoglobinopathies". Clin. Chim. Acta 439: 50-57, 2015.
[12] Ferreira, M.N.; Bonini-Domingos, C.R.; Estevão, I.F.; "Anti-Toxoplasma gondii antibodies in patients with beta-hemoglobinopathies: the first report in the Americas". BMC Res. Notes 10(1): 211, 2017.
[13] Ghaffari, J.; Vahidshahi, K.; Kosaryan, M.; "Humoral immune system state in β-thalassemia major". Med Glas (Zenica) 8(2): 192-196, 2011.
[14] Saeed, S.A.; Al-Aubaidi, I.K.; "Assessment of Interleukin-10 Levels in Iraqi Diabetic Type 2 Patients Infected with Toxoplasmosis". Adv. Life Sci. 10(1): 62-66, 2023.
[15] Karakaş, S.; Özlem, S.; Tellioglu, M.T.; Ertabaklar, H.; Ertug, S.; "Investigation of anti-Toxoplasma gondii IgG and IgM antibodies in beta-thalassemia major patients in Aydın province". Turk J Parasitol. 36(3): 133-136, 2012.
[16] Marasinghe, M.G.; Koehler, K.J.; "Statistical data analysis using SAS". JR Stat. Soc. Ser. A 183: 1829, 2018.
[17] Al-Aubaidi, I.K.; Saeed, S.A.; Jaaffar, A.I.; "Blood lymphocytes detection in Iraqi diabetic type 2 patients infected with chronic toxoplasmosis by using flow cytometry". Indian J Forensic Med Toxicol. 14(4): 2297-2303, 2020.
[18] El-Tantawy, N.; Darwish, A.; Eissa, A.; Eman, M.B.; "Seroprevalence of Toxoplasma gondii infection among beta-thalassemia major pediatric population: implications for transfusion transmissible toxoplasmosis". Pediatr Infect Dis J. 38(3): 236-240, 2019.
[19] Hopp, R.; Niebur, H.B.; "Persistent Hyper IgA as a Marker of Immune Deficiency: A Case Report". Antibodies (Basel) 11(2): 30, 2022.
[20] Gluba-Brzózka, A.; Franczyk, B.; Rysz-Górzyńska, M.; Rokicki, R.; Koziarska-Rościszewska, M.; Rysz, J.; "Pathomechanisms of immunological disturbances in β-thalassemia". Int J Mol Sci. 22(18): 9677, 1-13, 2021.
[21] Zko, S.S.; Al-Naftachi, M.T.; Al-Jawadi, W.A.; Alghrer, M.M.; "Seroprevalence of Toxoplasma gondii among thalassemia patients and its relation with some biochemical parameters". J Nat Sci Biol Med. 15(1): 119-124, 2024.
[22] Hanifehpour, H.; Samsam Shariat, S.K.; Ghafari, M.S.; Kheirandish, F.; Saber, V.; Fallahi, S.; "Serological and molecular diagnosis of Toxoplasma gondii infections in thalassemia patients". Iran J Parasitol. 14(1): 20-28, 2019.
[23] Wang, H.; Kim, S.J.; Lei, Y.; "Neutrophil extracellular traps in homeostasis and disease". Signal Transduct Target Ther. 9: 235, 2024.
[24] Al-Thamir, S.N.; Al-Hussainy, S.M.M.; "Effects of iron overload and treatment methods on serum levels of IgG, IgM, and IgA in beta thalassemia major patients". Med J Babylon. 8(3): 472-478, 2011.
[25] Daneshi, M.; "Serum immunoglobulin levels in splenectomized and nonsplenectomized patients with major beta-thalassemia". Iran J Immunol. 8(2): 95-98, 2011.
[26] Okab, H.F.; Saleh, M.B.; "Evaluation of the immune status of blood transfusion-dependent thalassemia in Thi-Qar Province, Iraq". J Educ Pure Sci. 9(2): 20-27, 2019.
[27] Javad, G.; Saeid, A.; Mohammadmehdi, N.; "Thalassemia and immune system dysfunction". Int J Curr Res. 3(12): 105-108, 2016.
[28] Asadov, C.; "Immunologic abnormalities in β-thalassemia". J Blood Disord Transfus. 5(7): 244, 2014.
[29] Goldberg, B.S.; Ackerman, M.E.; "Antibody-mediated complement activation in pathology and protection". Immunol Cell Biol. 98(4): 305-317, 2020.
[30] Qi, H.; Wei, J.; Gao, Y.; Yang, Y.; Li, Y.; Zhu, H.; Su, L.; Zhang, Y.; et al.; "Reg4 and complement factor D prevent the overgrowth of Escherichia coli in the mouse gut". Commun Biol. 3: 483, 2020.
[31] Buttari, B.; Profumo, E.; Caprari, P.; Massimi, S.; Sorrentino, F.; Maffei, L.; Gabbianelli, M.; Riganò, R.; "Phenotypical and functional abnormalities of circulating neutrophils in patients with β-thalassemia". Ann Hematol. 99(10): 2265–2277, 2020.
[32] Bazi, A.; Shahramian, I.; Yaghoobi, H.; Naderi, M.; Azizi, H.; "The role of immune system in thalassemia major: a narrative review". J Pediatr Rev. 6(2): 29-36, 2018.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Evan H. Sulaiman, Raghad N. Shihab, Ahmed Jabbar Obaid, Ahmed Abd Temur, Ahlam A. Alwan
This work is licensed under a Creative Commons Attribution 4.0 International License.
.jpg)
